Published October 23, 2018 | Version v1

Data from: Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems - the taliglucerase alfa story

  • 1. National Institute for Bioprocessing Research and Training
  • 2. Product Development, Protalix LTD, Carmiel, Israel*
  • 3. Research and Development, Protalix LTD, Carmiel, Israel*
  • 4. Bonnie Rup Consulting, LLC, Reading, Massachusetts, United States of America*

Description

Plants are a promising alternative for the production of biotherapeutics. Manufacturing in-planta adds plant specific glycans. To understand immunogenic potential of these glycans, we developed a validated method to detect plant specific glycan antibodies in human serum. Using this assay, low prevalence of pre-existing anti-plant glycan antibodies was found in healthy humans (13.5%) and in glucocerebrosidase-deficient Gaucher disease (GD) patients (5%). A low incidence (9% in naïve patient and none in treatment experienced patients) of induced anti-plant glycan antibodies was observed in GD patients after up to 30 months replacement therapy treatment with taliglucerase alfa, a version of human glucocerebrosidase produced in plant cells. Detailed evaluation of clinical safety and efficacy endpoints indicated that anti-plant glycan antibodies did not affect the safety or efficacy of taliglucerase alfa in patients. This study shows the benefit of using large scale human trials to evaluate the immunogenicity risk of plant derived glycans, and indicates no apparent risk related to anti-plant glycan antibodies.

Notes

Files

Study Results - ClinicalTrials NCT00376168.pdf

Files (474.0 kB)

Name Size
md5:db9a00bbfcf3644f838d2f7c53a79901
170.9 kB Preview Download
md5:44d55bff40c45c9e9f03db3bede74076
147.9 kB Preview Download
md5:f86927834193119f79281466e2705666
155.2 kB Preview Download

Additional details

Related works